ARTICLE | Company News
Activiomics, UCB deal
December 13, 2010 8:00 AM UTC
Activiomics will use its Targeted In-depth Quantification of Cell Signaling (TIQUAS) mass spectrometry technology to identify signaling mechanisms for antibodies from UCB. The antibodies are in develo...